Proxima A (GX29633) 31/03/2016
Prospective, multicentre epidemiological study of the progression of Geographic Atrophy secondary to Age-Related Macular Degeneration. This is an observational study which aims to recruit 360 patients with GA secondary to AMD. The population will have a higher number of patients showing positive results for the CFI biomarker profile by a proportion of 2:1.
The study’s duration will depend on the possible future availability of treatments approved for GA; if no treatment is approved, the expected maximum length of patient follow-up in this study is 48 months. Visual function and anatomical measurements will be taken on selection, at the basal moment (day 1) and then every 6 months.
The study’s principal aim is to learn more about the variability and the dynamic interval of visual function tests over time and the way these changes correlate with changes in the area of geographic atrophy (GA) in patients with GA secondary to age-related macular degeneration (AMD).
The secondary aims of this study are to assess the average variation with regard to the basal moment of the area of GA over time, assess the rates of a series of medical and ocular events of interest in the study patients, assess reading speed and variations over time in a series of results reported by the patients.
Principal inclusion criteria
Patients older than 50 with GA secondary to AMD without signs of prior or active choroidal neovascularisation (NVC) in both eyes.
If you are interested in taking part in a clinical trial, please call us at +34 93 595 01 55 and we will assess whether you are eligible.